BOLD Boundless Bio

NASDAQ
$2.66

Boundless Bio (BOLD) is expected to report earnings on November 6, 2026, before the market open.

Boundless Bio Reported Earnings
Friday, August 7, 2026 · 12:00 AM ET
Earnings Date
Nov 6
Friday · 7:00 AM ET
Earnings Whisper
-
vs -
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP -

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Boundless Bio

Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.